Werewolf Therapeutics, Inc. (HOWL)

US — Healthcare Sector
Peers: PMVP  LITS  PRLD  VXRT  RPTX  CBUS  IMUX  XBIT  CVM  CRVO 

Automate Your Wheel Strategy on HOWL

With Tiblio's Option Bot, you can configure your own wheel strategy including HOWL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol HOWL
  • Rev/Share 0.0
  • Book/Share 0.9218
  • PB 1.7195
  • Debt/Equity 0.2422
  • CurrentRatio 5.3022
  • ROIC -0.9091

 

  • MktCap 72474754.0
  • FreeCF/Share -1.355
  • PFCF -1.189
  • PE -0.9747
  • Debt/Assets 0.1085
  • DivYield 0
  • ROE -1.1187

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
HOWL
Published: October 03, 2025 by: GlobeNewsWire
Sentiment: Neutral

WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland. Details for the poster presentations are as follows:

Read More
image for news Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
HOWL
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
HOWL
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year –

Read More
image for news Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

About Werewolf Therapeutics, Inc. (HOWL)

  • IPO Date 2021-04-30
  • Website https://werewolftx.com
  • Industry Biotechnology
  • CEO Daniel J. Hicklin
  • Employees 46
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.